IGMS IGM Biosciences Inc.

18.77
-1.17  -6%
Previous Close 19.94
Open 19.51
52 Week Low 19.67
52 Week High 127.11
Market Cap $609,306,315
Shares 32,461,711
Float 8,426,515
Enterprise Value $379,174,314
Volume 318,156
Av. Daily Volume 298,604
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Fostroxacitabine Bralpamide (MIV-818)
Liver cancer
Phase 1/2
Phase 1/2
Phase 1b/2a combination study initiated, noted December 14, 2021. Phase 1b/2a data reported that drug induced DNA-damage was observed in all on-treatment tumor samples, noted January 21, 2022.
IGM-2323
Relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL)
Phase 1
Phase 1
Phase 1 initial data presented at ASH December 5, 2020. 2/14 complete responses. Phase 1 data presented showed novel bispecific IgM antibody is active in heavily pre-treated patients (n=40). Overall, of the 38 patients evaluable for efficacy, 11 patients showed a response, 8 of which were complete responses. Phase 2 initiated to assess the safety and efficacy of two doses (100 mg and 300 mg), noted December 11, 2021.
IGM-8444
Solid Cancers and Non-Hodgkin’s Lymphoma
Phase 1
Phase 1
Phase 1 clinical trial initiated, noted November 4, 2021.
Birinapant and IGM-8444
Solid Tumors
Phase 1
Phase 1
Phase 1 first patient dosed, noted November 4, 2021.
IGM-6268
COVID-19
Phase 1
Phase 1
Phase 1 trial to commence by year end 2021.
IGM-7354
Solid tumors
Phase 1
Phase 1
Phase 1 IND filing due by 2022.

Latest News

  1. STOCKHOLM, Jan. 21, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR-B) today announces that an e-poster entitled "Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver" will be presented at the European Association for the Study of the Liver (EASL) Liver Cancer Summit 3-4 February. The Abstract (PO-221) is available on the EASL website (https://easl.eu/wp-content/uploads/2022/01/LCS-2022-Abstract-book-final.pdf).

    For additional information, please contact
    Magnus Christensen, Interim CEO and CFO, Medivir AB
    Telephone: +46 8 5468 3100
    E-mail:

    About fostroxacitabine bralpamide
    Fostroxacitabine bralpamide (also named MIV-818) is a pro-drug designed…

    STOCKHOLM, Jan. 21, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR-B) today announces that an e-poster entitled "Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver" will be presented at the European Association for the Study of the Liver (EASL) Liver Cancer Summit 3-4 February. The Abstract (PO-221) is available on the EASL website (https://easl.eu/wp-content/uploads/2022/01/LCS-2022-Abstract-book-final.pdf).

    For additional information, please contact

    Magnus Christensen, Interim CEO and CFO, Medivir AB

    Telephone: +46 8 5468 3100

    E-mail:

    About fostroxacitabine bralpamide

    Fostroxacitabine bralpamide (also named MIV-818) is a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer. Fostroxacitabine bralpamide has completed a phase 1b monotherapy study, and a combination study in HCC was recently initiated.

    About primary liver cancer

    Primary liver cancer is the third leading cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver. Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high. There are 42,000 patients diagnosed with primary liver cancer per year in the US and current five-year survival is 11 percent. HCC is a heterogeneous disease with diverse etiologies, and lacks defining mutations observed in many other cancers. This has contributed to the lack of success of molecularly targeted agents in HCC. The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need.

    About Medivir

    Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (MIV-818), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.

    Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (NASDAQ:IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (Stockholm: MVIR-B) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/medivir/r/biomarker-data-from-the-fostroxacitabine-bralpamide-phase-1-study-to-be-presented-at-the-easl-liver-,c3490352

    The following files are available for download:

     

    Cision View original content:https://www.prnewswire.com/news-releases/biomarker-data-from-the-fostroxacitabine-bralpamide-phase-1-study-to-be-presented-at-the-easl-liver-cancer-summit-301465712.html

    SOURCE Medivir

    View Full Article Hide Full Article
  2. STOCKHOLM, Jan. 18, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR-B) today announced that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) fostroxacitabine bralpamide as the official generic name for the company's patented candidate drug MIV-818, which is in clinical development in primary liver cancer.

    Medivir's main project, fostroxacitabine bralpamide (MIV-818), is the company's proprietary candidate drug with a unique mechanism of action, which makes fostroxacitabine bralpamide attractive to be combined with a multitude of other drugs for the treatment of hepatocellular carcinoma (HCC). In the ongoing study, fostroxacitabine bralpamide is administered in two different combinations, either…

    STOCKHOLM, Jan. 18, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR-B) today announced that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) fostroxacitabine bralpamide as the official generic name for the company's patented candidate drug MIV-818, which is in clinical development in primary liver cancer.

    Medivir's main project, fostroxacitabine bralpamide (MIV-818), is the company's proprietary candidate drug with a unique mechanism of action, which makes fostroxacitabine bralpamide attractive to be combined with a multitude of other drugs for the treatment of hepatocellular carcinoma (HCC). In the ongoing study, fostroxacitabine bralpamide is administered in two different combinations, either with Lenvima®, a tyrosine kinase inhibitor, or with Keytruda®, an anti-PD-1 checkpoint inhibitor.

    - "We are now able to use a generic name for our candidate drug, and for us that is an important step towards a product for the treatment of HCC," said Magnus Christensen, interim CEO and CFO of Medivir.

    For further information, please contact:

    Magnus Christensen, Interim CEO and CFO, Medivir AB

    Phone: +46 (0)8 5468 3100

    E-mail:

    About fostroxacitabine bralpamide

    Fostroxacitabine bralpamide (also named MIV-818) is a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer. Fostroxacitabine bralpamide has completed a phase 1b monotherapy study, and a combination study in HCC was recently initiated.

    About primary liver cancer

    Primary liver cancer is the third leading cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver. Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high. There are 42,000 patients diagnosed with primary liver cancer per year in the US and current five-year survival is 11 percent. HCC is a heterogeneous disease with diverse etiologies, and lacks defining mutations observed in many other cancers. This has contributed to the lack of success of molecularly targeted agents in HCC. The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need.

    About Medivir

    Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (MIV-818), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. 

    Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (NASDAQ:IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (Stockholm: MVIR-B) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/medivir/r/medivir-s-miv-818-obtains-the-international-nonproprietary-name-fostroxacitabine-bralpamide,c3487790

    The following files are available for download:

     

    Cision View original content:https://www.prnewswire.com/news-releases/medivirs-miv-818-obtains-the-international-nonproprietary-name-fostroxacitabine-bralpamide-301462497.html

    SOURCE Medivir

    View Full Article Hide Full Article
  3. STOCKHOLM, Jan. 17, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that Jens Lindberg will assume his position as CEO on January 24, 2022. Magnus Christensen, who has been interim CFO since the Annual General Meeting on May 5, 2021 will remain as CFO of Medivir.

    Jens Lindberg joins Medivir from his current position as VP Commercial at Sedana Medical, where he also served as acting CEO of the company during Q2-Q3 2021. Prior to that, during his twenty-five years at AstraZeneca, Jens held numerous roles, spanning local and global areas of responsibility. In the later years at AstraZeneca, his roles were primarily in the area of oncology with responsibility for developing global product strategy and global commercial responsibility…

    STOCKHOLM, Jan. 17, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that Jens Lindberg will assume his position as CEO on January 24, 2022. Magnus Christensen, who has been interim CFO since the Annual General Meeting on May 5, 2021 will remain as CFO of Medivir.

    Jens Lindberg joins Medivir from his current position as VP Commercial at Sedana Medical, where he also served as acting CEO of the company during Q2-Q3 2021. Prior to that, during his twenty-five years at AstraZeneca, Jens held numerous roles, spanning local and global areas of responsibility. In the later years at AstraZeneca, his roles were primarily in the area of oncology with responsibility for developing global product strategy and global commercial responsibility in product development. Jens was also responsible for running the local Business Unit Oncology in Nordic-Baltic region with significant commercial success.

    - I'm really pleased that Jens can join so quickly and look forward to welcoming him to Medivir. His solid experience from the oncology field is very important for Medivir in the exciting phase the company is in, says Uli Hacksell, Chairman of the Board of Medivir AB.

    - I would also like to thank Magnus Christensen, who since the Annual General Meeting on May 5, 2021 has tirelessly and committedly handled the responsibility as interim CEO and at the same time carried out his work as CFO. Thanks to Magnus and the entire team's efforts in 2021, Medivir's work to develop innovative drugs for the treatment of cancer has been able to continue without losing pace, Uli Hacksell concludes.

    For further information, please contact:

    Dr Uli Hacksell, Chairman of the Board, Medivir AB

    Phone: +46 (0)8 5468 3100.

    E-mail:  

    About Medivir

    Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. 

    Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (NASDAQ:IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/medivir/r/jens-lindberg-takes-office-as-ceo-of-medivir-on-january-24,c3487068

    The following files are available for download:

    Cision View original content:https://www.prnewswire.com/news-releases/jens-lindberg-takes-office-as-ceo-of-medivir-on-january-24-301461858.html

    SOURCE Medivir

    View Full Article Hide Full Article
  4. STOCKHOLM, Jan. 10, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright BioConnect Virtual Conference, January 10-13.

    The presentation will be available via Medivirs website; www.medivir.com.

    More information about the event is available at the organizer's website: https://hcwevents.com/bioconnect/.

    For additional information, please contact

    Magnus Christensen, Interim CEO and CFO
    Telephone: +46 8 5468 3100
    E-mail:  

    Medivir in brief

    Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or…

    STOCKHOLM, Jan. 10, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright BioConnect Virtual Conference, January 10-13.

    The presentation will be available via Medivirs website; www.medivir.com.

    More information about the event is available at the organizer's website: https://hcwevents.com/bioconnect/.

    For additional information, please contact

    Magnus Christensen, Interim CEO and CFO

    Telephone: +46 8 5468 3100

    E-mail:  

    Medivir in brief

    Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. 

    Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (NASDAQ:IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/medivir/r/medivir-to-present-at-the-h-c--wainwright-bioconnect-virtual-conference,c3483344

    The following files are available for download:

    Cision View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-hc-wainwright-bioconnect-virtual-conference-301456928.html

    SOURCE Medivir

    View Full Article Hide Full Article
  5. MOUNTAIN VIEW, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 10:30 a.m. EST.

    A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.

    About IGM Biosciences, Inc.
    Headquartered in Mountain…

    MOUNTAIN VIEW, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 10:30 a.m. EST.

    A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.

    About IGM Biosciences, Inc.

    Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

    Contact

    Argot Partners

    David Pitts

    212-600-1902



    Primary Logo

    View Full Article Hide Full Article
View All IGM Biosciences Inc. News